Combination of Gemcitabine and Imatinib Mesylate in Pemetrexed-pretreated Patients With Pleural Mesothelioma

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a phase II, monocentric study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with MPM expressing PDGFR-beta and/or C-kit by Immunohistochemistry (IHC). Treatment will be done until disease progression, or patient refusal or withdrawal of patient consent, or unacceptable toxicity
Epistemonikos ID: be457305f5f7c0b7d773754fba193d98f0e4b5bb
First added on: May 12, 2024